Skip to content
Generic filters
Exact matches only
Search in title
Search in content
Search in excerpt

EURORDIS welcomes promising emphasis on rare diseases in EU Life Sciences Strategy 

July 2025

2 July 2025, Brussels – EURORDIS–Rare Diseases Europe warmly welcomes the strong emphasis in the EU Life Sciences Strategy on the potential of life sciences to transform the lives of the 30 million people living with a rare disease across Europe. 

Unveiled today by the European Commission, the Strategy aims to reinforce Europe’s global competitiveness in life sciences while aligning innovation with public health needs and societal values. It charts the course for future EU action and investment across biomedical research, regulation, and access to health technologies – with a strong focus on scientific excellence and shared global challenges.

The Strategy reflects many of the priorities long championed by EURORDIS and the wider rare disease community. The potential of life sciences to address rare diseases also featured prominently in the broad range of submissions from civil society and industry to the European Commission’s Call for Evidence earlier this year. 

Valentina Bottarelli, Head of Policy and Public Affairs at EURORDIS, said: 

We are delighted that this Strategy clearly acknowledges the central role rare diseases must play in Europe’s life sciences ambition.

Today, 95% of rare diseases still lack an approved treatment – a staggering gap that demands urgent scientific and policy action. But rare diseases are not only defined by unmet need; they are also powerful engines of innovation. More than 70% have a genetic origin, making them ideal candidates for breakthroughs in genomics, diagnostics, and advanced therapies – many of which are now being applied to more common conditions. Several EU countries have already used rare diseases as launchpads for progress in precision medicine. By scaling this approach, the EU has a real opportunity to restore its global leadership in life sciences.

In this context, the Commission’s explicit focuses on rare diseases – alongside its support for advanced therapies, multi-country clinical trials, and more adaptive regulatory tools – is both timely and essential.

We are deeply grateful that the European Commission has listened to our community’s voices. Many of the priorities we have long championed – from strengthening European Reference Networks to cross-border research and investing in workforce and manufacturing capacity, to improving data use through interoperability – are clearly embedded in this Strategy.

We nonetheless also welcome that progress will be tracked through indicators such as business investment in R&D and the number of multi-country clinical trials – both of which are critical to advancing innovation in areas like rare diseases, where research is often underfunded and patient populations too small to be addressed at national level alone.

What matters now is that implementation is bold, well-resourced, and inclusive of patient organisations at every step – including through meaningful participation in the new Life Sciences Coordination Board. Regulation must work not only for large companies, but also for academic researchers and non-profit developers working on the most neglected conditions.

It is also essential that new investment platforms – such as the strategic interface linking startups, investors, and industry – ensure equitable access for rare disease innovators, especially early-stage, high-risk ventures with strong public value but limited commercial backing.

As Europe pioneers advanced therapies, trust-building must remain a priority. We strongly support the Commission’s plans for citizen engagement and public dialogue around biotechnology and ATMPs – embedding societal values from the outset will be key to long-term success.

With the right coordination and investment, including dedicated funding commitments and fresh earmarked resources, this Strategy can signify the beginning of a new era for rare disease research and care in Europe – one that turns scientific promise into lasting change for millions of families.

Many of the Strategy’s actions reflect the priorities EURORDIS shared with the European Commission in April, and we – together with our members – remain ready to contribute further 

About EURORDIS-Rare Diseases Europe 

EURORDIS-Rare Diseases Europe is a unique, non-profit alliance of over 1,000 rare disease organisations from 74 countries that work together to improve the lives of the 30 million people living with a rare disease in Europe. By connecting people, families, and rare disease groups, as well as by bringing together all stakeholders and mobilising the rare disease community, EURORDIS strengthens the patient voice and shapes research, policies, and services. 

Contact 

Julien Poulain 
Communications Manager, EURORDIS-Rare Diseases Europe
Julien.poulain@eurordis.org 
+33 6 42 98 14 32